FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964170047> ?p ?o ?g. }

• W1964170047 endingPage "e33672" @default.
• W1964170047 startingPage "e33672" @default.
• W1964170047 abstract "Background Despite funding constraints for treatment programmes in Africa, the costs and economic consequences of routine laboratory monitoring for efficacy and toxicity of antiretroviral therapy (ART) have rarely been evaluated. Methods Cost-effectiveness analysis was conducted in the DART trial (ISRCTN13968779). Adults in Uganda/Zimbabwe starting ART were randomised to clinically-driven monitoring (CDM) or laboratory and clinical monitoring (LCM); individual patient data on healthcare resource utilisation and outcomes were valued with primary economic costs and utilities. Total costs of first/second-line ART, routine 12-weekly CD4 and biochemistry/haematology tests, additional diagnostic investigations, clinic visits, concomitant medications and hospitalisations were considered from the public healthcare sector perspective. A Markov model was used to extrapolate costs and benefits 20 years beyond the trial. Results 3316 (1660LCM;1656CDM) symptomatic, immunosuppressed ART-naive adults (median (IQR) age 37 (32,42); CD4 86 (31,139) cells/mm3) were followed for median 4.9 years. LCM had a mean 0.112 year (41 days) survival benefit at an additional mean cost of $765 [95%CI:685,845], translating into an adjusted incremental cost of $7386 [3277,dominated] per life-year gained and $7793 [4442,39179] per quality-adjusted life year gained. Routine toxicity tests were prominent cost-drivers and had no benefit. With 12-weekly CD4 monitoring from year 2 on ART, low-cost second-line ART, but without toxicity monitoring, CD4 test costs need to fall below $3.78 to become cost-effective (<3xper-capita GDP, following WHO benchmarks). CD4 monitoring at current costs as undertaken in DART was not cost-effective in the long-term. Conclusions There is no rationale for routine toxicity monitoring, which did not affect outcomes and was costly. Even though beneficial, there is little justification for routine 12-weekly CD4 monitoring of ART at current test costs in low-income African countries. CD4 monitoring, restricted to the second year on ART onwards, could be cost-effective with lower cost second-line therapy and development of a cheaper, ideally point-of-care, CD4 test." @default.
• W1964170047 created "2016-06-24" @default.
• W1964170047 creator A5006641773 @default.
• W1964170047 creator A5015958019 @default.
• W1964170047 creator A5022635990 @default.
• W1964170047 creator A5024124122 @default.
• W1964170047 creator A5028823785 @default.
• W1964170047 creator A5029861967 @default.
• W1964170047 creator A5030902925 @default.
• W1964170047 creator A5039097464 @default.
• W1964170047 creator A5039635643 @default.
• W1964170047 creator A5040923448 @default.
• W1964170047 creator A5043684973 @default.
• W1964170047 creator A5044248283 @default.
• W1964170047 creator A5044933203 @default.
• W1964170047 creator A5047943091 @default.
• W1964170047 creator A5053442063 @default.
• W1964170047 creator A5068494724 @default.
• W1964170047 creator A5070322756 @default.
• W1964170047 creator A5086489360 @default.
• W1964170047 creator A5086742423 @default.
• W1964170047 creator A5089346808 @default.
• W1964170047 date "2012-04-24" @default.
• W1964170047 modified "2023-09-26" @default.
• W1964170047 title "Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe" @default.
• W1964170047 cites W1989069382 @default.
• W1964170047 cites W2019965085 @default.
• W1964170047 cites W2021084785 @default.
• W1964170047 cites W2037884356 @default.
• W1964170047 cites W2048706368 @default.
• W1964170047 cites W2059780880 @default.
• W1964170047 cites W2070629478 @default.
• W1964170047 cites W2083226492 @default.
• W1964170047 cites W2093439375 @default.
• W1964170047 cites W2099825992 @default.
• W1964170047 cites W2100856823 @default.
• W1964170047 cites W2108259145 @default.
• W1964170047 cites W2114267004 @default.
• W1964170047 cites W2125470091 @default.
• W1964170047 cites W2126078440 @default.
• W1964170047 cites W2133166320 @default.
• W1964170047 cites W2137850028 @default.
• W1964170047 cites W2139963961 @default.
• W1964170047 cites W2143621348 @default.
• W1964170047 cites W2165338002 @default.
• W1964170047 cites W2168405519 @default.
• W1964170047 cites W2172106821 @default.
• W1964170047 cites W2320048258 @default.
• W1964170047 cites W3106889297 @default.
• W1964170047 doi "https://doi.org/10.1371/journal.pone.0033672" @default.
• W1964170047 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3335836" @default.
• W1964170047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22545079" @default.
• W1964170047 hasPublicationYear "2012" @default.
• W1964170047 type Work @default.
• W1964170047 sameAs 1964170047 @default.
• W1964170047 citedByCount "25" @default.
• W1964170047 countsByYear W19641700472013 @default.
• W1964170047 countsByYear W19641700472014 @default.
• W1964170047 countsByYear W19641700472015 @default.
• W1964170047 countsByYear W19641700472016 @default.
• W1964170047 countsByYear W19641700472017 @default.
• W1964170047 countsByYear W19641700472018 @default.
• W1964170047 countsByYear W19641700472019 @default.
• W1964170047 countsByYear W19641700472020 @default.
• W1964170047 countsByYear W19641700472021 @default.
• W1964170047 countsByYear W19641700472022 @default.
• W1964170047 crossrefType "journal-article" @default.
• W1964170047 hasAuthorship W1964170047A5006641773 @default.
• W1964170047 hasAuthorship W1964170047A5015958019 @default.
• W1964170047 hasAuthorship W1964170047A5022635990 @default.
• W1964170047 hasAuthorship W1964170047A5024124122 @default.
• W1964170047 hasAuthorship W1964170047A5028823785 @default.
• W1964170047 hasAuthorship W1964170047A5029861967 @default.
• W1964170047 hasAuthorship W1964170047A5030902925 @default.
• W1964170047 hasAuthorship W1964170047A5039097464 @default.
• W1964170047 hasAuthorship W1964170047A5039635643 @default.
• W1964170047 hasAuthorship W1964170047A5040923448 @default.
• W1964170047 hasAuthorship W1964170047A5043684973 @default.
• W1964170047 hasAuthorship W1964170047A5044248283 @default.
• W1964170047 hasAuthorship W1964170047A5044933203 @default.
• W1964170047 hasAuthorship W1964170047A5047943091 @default.
• W1964170047 hasAuthorship W1964170047A5053442063 @default.
• W1964170047 hasAuthorship W1964170047A5068494724 @default.
• W1964170047 hasAuthorship W1964170047A5070322756 @default.
• W1964170047 hasAuthorship W1964170047A5086489360 @default.
• W1964170047 hasAuthorship W1964170047A5086742423 @default.
• W1964170047 hasAuthorship W1964170047A5089346808 @default.
• W1964170047 hasBestOaLocation W19641700471 @default.
• W1964170047 hasConcept C112930515 @default.
• W1964170047 hasConcept C126322002 @default.
• W1964170047 hasConcept C127454912 @default.
• W1964170047 hasConcept C127598652 @default.
• W1964170047 hasConcept C142462285 @default.
• W1964170047 hasConcept C144024400 @default.
• W1964170047 hasConcept C149923435 @default.
• W1964170047 hasConcept C160735492 @default.
• W1964170047 hasConcept C162324750 @default.
• W1964170047 hasConcept C18903297 @default.

• next